Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)

NCT06677307 is registered in ClinicalTrials.gov with Korro Bio, Inc. as lead sponsor.

NCT NCT06677307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)
Lead sponsor
Korro Bio, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 13, 2025
Completion date
December 15, 2025
Enrollment
42 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

aatd, alpha-1 anti-trypsin deficiency